• Aaron J Small, James L Araujo, Cadman L Leggett, Aaron H Mendelson, Anant Agarwalla, Julian A Abrams, Charles J Lightdale, Timothy C Wang, Prasad G Iyer, Kenneth K Wang, Anil K Rustgi, Gregory G Ginsberg, Kimberly A Forde, Phyllis A Gimotty, James D Lewis, Gary W Falk, and Meenakshi Bewtra.
• Department of Medicine, Division of Gastroenterology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: asmall27@gmail.com.
• Gastroenterology. 2015 Sep 1; 149 (3): 567-76.e3; quiz e13-4.

Background & AimsBarrett's esophagus (BE) with low-grade dysplasia (LGD) can progress to high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC). Radiofrequency ablation (RFA) has been shown to be an effective treatment for LGD in clinical trials, but its effectiveness in clinical practice is unclear. We compared the rate of progression of LGD after RFA with endoscopic surveillance alone in routine clinical practice.MethodsWe performed a retrospective study of patients who either underwent RFA (n = 45) or surveillance endoscopy (n = 125) for LGD, confirmed by at least 1 expert pathologist, from October 1992 through December 2013 at 3 medical centers in the United States. Cox regression analysis was used to assess the association between progression and RFA.ResultsData were collected over median follow-up periods of 889 days (interquartile range, 264-1623 days) after RFA and 848 days (interquartile range, 322-2355 days) after surveillance endoscopy (P = .32). The annual rates of progression to HGD or EAC were 6.6% in the surveillance group and 0.77% in the RFA group. The risk of progression to HGD or EAC was significantly lower among patients who underwent RFA than those who underwent surveillance (adjusted hazard ratio = 0.06; 95% confidence interval: 0.008-0.48).ConclusionsAmong patients with BE and confirmed LGD, rates of progression to a combined end point of HGD and EAC were lower among those treated with RFA than among untreated patients. Although selection bias cannot be excluded, these findings provide additional evidence for the use of endoscopic ablation therapy for LGD.Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.

31 keywords...

hide…